SweetFreedom grew out of a personal experience.

When my daughter was diagnosed with Type 1 Diabetes, we were told: "The beta cells can't be saved - you'll learn to live with it." We set out to find whether that was actually true. What grew from that is a community-backed research initiative with one central goal: to seriously, responsibly, and transparently examine whether the damage to beta cells can be halted, and whether a process of recovery may be possible.

Not as a promise. Not as a miracle solution. But as structured work, grounded in research and physician supervision.

A Problem the World Still Only Manages

This is not a rare or shrinking problem. 9.5 million people live with Type 1 Diabetes worldwide, with more than 513,000 newly diagnosed every year. Roughly $90 billion is spent globally each year simply to manage the disease - without ever addressing its underlying cause. And despite a century of modern insulin and glucose monitoring, a person living with T1D still loses an average of about 12 years of life expectancy.

The standard model treats T1D as an irreversible autoimmune fate. The technology for delivering insulin has improved enormously. The underlying question - whether the process itself can be slowed, halted, or partly reversed - has received far less attention.

The Question We Never Stopped Asking

For over a century, Type 1 Diabetes has been treated as an irreversible autoimmune condition: the immune system destroyed the beta cells, there is no way back, and all that remains is to manage it with insulin.

But research from recent years tells a more complex - and perhaps more hopeful - story. It turns out beta cells are not necessarily erased completely. That they are capable of regenerating. And that what keeps them damaged may not be the immune system alone, but a hostile biological environment that prevents them from recovering.

The hypothesis we are testing: functional restoration may be possible - if the burdens on the body are reduced in the correct sequence, giving the remaining cells a chance to recover.

This is not a promise of a cure. It is a structured attempt, under physician supervision, to test whether the assumption of irreversibility was accepted too soon.

What Has Emerged in the Last 8 Years

Five pieces of recent research that, when assembled together, paint a new picture of the disease:

1. Beta cells were not "murdered" - they called for help. Under stress, beta cells emit inflammatory distress signals, and the immune system responds to that call. They are active participants in what happens to them, not passive victims.

2. It all begins in the gut - months before the antibodies. The TEDDY study found that in children who developed diabetes, the protective gut bacteria disappeared and the gut wall was breached, even before the first antibodies appeared.

3. A virus hiding in the pancreas. Enteroviral presence has been found in the pancreas of people with Type 1 Diabetes, at far higher rates than in a healthy population. Not an acute infection - a small, persistent "fire."

4. Beta cells can regenerate. The belief that adult beta cells cannot proliferate has been overturned. A significant increase in beta-cell mass has been demonstrated under laboratory conditions. It has not yet been proven in humans with diabetes - but it shows that it is possible.

5. The pancreas is a whole system. Type 1 Diabetes is a disease of the entire "islet," not only the beta cells. Real restoration must address the whole system.

If beta cells survive, and if they can regenerate, then perhaps the problem is not only an aggressive immune system, but an environment that prevents them from recovering. And that is something we can try to change.

The Sequential Restoration Model (v4.3)

Most attempts to regenerate beta cells fail, and we think we know why: they try to grow new cells inside an environment that is still hostile. It's like trying to rebuild a house while it is still on fire - first you have to put out the flames.

That's why the model is built in a specific order. The protocol is complete (version 4.3) and is already in its first physician-supervised implementation. Each phase is measured by tests, and progression to the next depends on a measurable biological improvement - not on a timeline:

Phase 1 - Put Out the Fire. Restore the gut barrier and protective bacteria, and calm the inflammation originating in the gut. The goal: lower the baseline burden on the body.

Phase 2 - Clear the Ground. Address persistent stressors - viral signatures and toxic burden that keep the cells in distress.

Phase 3 - Stabilize the Pancreas. Stabilize the hormonal communication between alpha and beta cells, before attempting to encourage regeneration.

Phase 4 - Rebuild. Encourage beta-cell regeneration - only after the environment has calmed and stabilized.

Everything is test-based and conducted under physician supervision. No phase transition happens without a measurable sign that the body is ready. It is the sequence - not any single ingredient - that the model is built on.

From Case Series to Clinical Trial

We are building a staged research pathway, designed to test whether sequential restoration can produce measurable functional recovery - under physician supervision and with transparency.

The immediate next step: a physician-supervised case series. This stage is designed and ready to launch, and securing the funding to begin it is our immediate priority. The first cohort is 6 families, with 12-month biomarker tracking. The structured case series needs funding to begin. This is an observational stage in a private, physician-supervised setting under informed parental consent.

The next stage: a Phase 2a clinical trial. A controlled trial of 20-60 participants with a contracted Principal Investigator and independent oversight, with C-peptide as the primary measure of pancreatic function.

Why We Turn to Supporters

An approach like this one has no natural funder.

Pharmaceutical development is built around patentable molecules - and you cannot patent a dietary fiber, a clinical probiotic, or a botanical compound. Public research grants are built to fund one narrow hypothesis at a time - not a multi-phase approach that crosses immunology, gastroenterology, and endocrinology at once. So the integrated question falls through the gap between the two systems: not for lack of science, but for lack of a business model.

Our goal for the founding year is €350,000 (approximately $380,000) - the full budget required to build the team, run the first case series, and produce the earliest real-world evidence.

Support does not fund a result. It enables the serious, responsible, and ongoing pursuit of one.

Founding Year Budget - €350,000

The founding year is funded in two stages, separated by a decision gate (Gate 1). Stage A builds the clinical team and the operational foundation. Stage B runs the case series - and is only deployed once the team is actually contracted and in place. The budget is managed gradually, aligned with the actual scope of activity, with an ongoing commitment to transparency and community reporting. We're fully open about where the work is heading, how it's progressing, and what we find - while keeping the specifics of the protocol itself protected.

STAGE A - Foundation & Team (Months 1-6): €154,000

1. Clinical Setup & Team Building - €87,500 (25%) Recruiting the clinical team, site agreements, regulatory and ethics groundwork, and laboratory selection.

2. Scientific Research & Protocol Refinement - €42,000 (12%) Founder-led evidence synthesis, protocol updates, and development of the biomarker framework.

3. Fundraising & Communications - €24,500 (7%) Donor development, materials, and ongoing knowledge-sharing with the community.

GATE 1 - Stage B is released only once the clinical team is contracted and the foundation is verifiably in place.

STAGE B - Case-Series Execution (Months 6-12): €196,000

4. Lab Assays & Biomarker Diagnostics - €52,500 (15%) Case-series testing (microbiome, organic acids, toxic panels, C-peptide and related markers), professional interpretation, and monitoring tools.

5. Participant Supplements & Materials - €49,000 (14%) The full protocol supplements, provided free of charge to the first cohort families.

6. Scientific & Partnership Development - €49,000 (14%) Conferences and working sessions, publishing, biostatistics scoping, professional literature and database subscriptions.

7. Clinical Coordination & Oversight - €45,500 (13%) Physician oversight, researcher and site coordination, safety monitoring, and governance.

Blended monthly burn across the year is approximately €29,000 per month. In parallel, the Phase 2a pilot study is being conceptualized and will only be implemented following the maturation of the professional framework, appropriate ethical and regulatory milestones, and the raising of dedicated funding.

Participation and Partnership Paths

Monthly support is what makes the founding year reachable - and what keeps the work stable beyond it. Every path below counts toward the €350,000 founding-year goal.

🟢 Community Path - €25-125 per month Intended for parents of children with diabetes and for people living with diabetes who wish to stay connected to what is happening, receive ongoing updates and research summaries, and be part of a learning, investigative community.

🟦 Research Partner - €750-1,250 per month Intended for individuals who wish to be active partners in a serious research effort. Participation sustains the ongoing research and testing, enables deeper exploration of complex directions, and supports the stable operation of the working group. Partners receive substantive updates on the direction and progress of the work, and are included in discussions around the dilemmas and questions the research is engaging with.

🟪 Anchor Partner - €2,000-5,000 per month Anchor partners are the individuals who make it possible for the framework to exist over time. Participation includes close partnership in the work, periodic in-depth conversations, and recognition as a founding partner of the framework. This is not a management role, but a form of partnership that enables real, stable, and long-term research work.

⭐ Founding Grant - €350,000 A single founding grant covers the entire first year, released in two stages around Gate 1. If you are considering a contribution at this scale, or represent a foundation, we would welcome a direct conversation.

Professional Collaborations and Sponsorships

SweetFreedom is open to collaboration with companies and professional bodies in the fields of nutritional supplements, testing laboratories, herbal medicine, and biological monitoring. Partnerships are based on responsibility, transparency, and shared learning, with no commercial promotion and no obligation to recommend.

Clear Boundaries

SweetFreedom is a community-backed research initiative. It does not constitute medical treatment and does not replace personal medical advice. There is no promise of a cure, and no individual treatment recommendations. Every health decision should be made under the guidance of a physician. Precisely because the ambition is high - the discipline must be higher.

Who This Is For - And Who It Is Not

This is for those willing to stay with the question. For those who understand that deep processes take time. For those who choose to believe that more can be discovered than is currently known. It is not for those seeking a quick solution or an emotional story.

Joining the SweetFreedom Framework

You can support SweetFreedom through any of the buttons on this page - the "Donate" button or the "Join" buttons for the different paths. Support can be provided as a one-time contribution or as monthly payments, which grant participation in one of the paths according to the selected amount. 
🟢 Donations are tax-deductible across multiple jurisdictions.

In Memory of Hava Ben Ami (of blessed memory)

The work of SweetFreedom is also dedicated to the memory of Hava Ben Ami, who was murdered on October 7th, 2023 at Kibbutz Be'eri. Hava dreamed of seeing her granddaughter recover from diabetes, and believed that one day we would understand more - and find a way to stop the damage and allow a process of recovery. Her quiet faith continues to accompany this path.

In Closing

SweetFreedom does not promise a cure. It promises not to give up on the hope that one can be found - and to explore that possibility with courage, responsibility, and transparency.

Join us.